申请人:ALNYLAM PHARMACEUTICALS, INC.
公开号:US20150111841A1
公开(公告)日:2015-04-23
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.